Qilu pharmaceutical imitates trelagriptin, a heavy-duty hypoglycemic drug once a week

Not long ago, the world's first weekly oral hypoglycemic drug, trilagliptin, was approved for marketing in Japan (under the trade name of zafatek), developed by Takeda pharmaceutical, known as the heavyweight bomb in the field of diabetes At present, trogliptin is only listed in Japan and has not yet submitted clinical application in China Qilu pharmaceutical took the lead in the first time to copy the 3.1 class of tragliptin According to insight China Pharma data database, Qilu pharmaceutical's application for trogliptin was undertaken by CDE on April 24, 2015 and entered the review center, involving the acceptance numbers of cxhl1500819, cxhl1500820 and cxhl1500821 The advantage of once a week oral administration of trogliptin makes the market competition of DPP-4 inhibitors more fierce, which makes januvia (sigletin), the once daily DPP-4 inhibitor that easily leads the market, unable to relax its vigilance Meanwhile, it also leaves behind the competitive product omarigriptin of MSD Such a good product, the domestic enterprises will not miss the good opportunity of imitation However, the patent of Takeda Pharmaceutical (wo200703350, cn101374523b) expires on September 13, 2026 in China, which is ten years away from now Qilu pharmaceutical should consider how to avoid the patent while trying to copy and apply first More than 20 DPP-4 inhibitors have been declared in China, among which the listed DPP-4 inhibitors are all imported drugs, including shagliptin jointly developed by Squibb and AstraZeneca, liggliptin of bringlingham, once daily administration of siggliptin by mosadong, agliptin of Takeda pharmaceutical, wiggliptin and metformin / wiggliptin of Novartis pharmaceutical In addition, Qilu pharmaceutical is also fond of DPP-4 inhibitor market In addition to tragliptin, there are five varieties in the application, four of which have submitted listing applications It can be seen that the heat of DPP-4 inhibitors has not dissipated, and the competition is also continuing.